Next-Generation Pediatric Immunotherapy
Lead: Dr. James Chen
Developing safer, more effective immunotherapy treatments specifically designed for pediatric cancer patients. Current treatments designed for adults often cause severe side effects in children; this research aims to change that.
Key Objectives
- Engineer child-specific CAR-T cell therapies
- Reduce treatment-related side effects by 60%
- Expand clinical trial access for underserved populations
- Develop predictive biomarkers for treatment response